DK139056B
(da)
*
|
1976-04-06 |
1978-12-11 |
Nordisk Insulinlab |
Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse.
|
US4164495A
(en)
*
|
1976-04-06 |
1979-08-14 |
Nordisk Insulinlaboratorium |
Method of recovering immunoglobulin using a polyol and an alkanoic acid
|
US4124576A
(en)
*
|
1976-12-03 |
1978-11-07 |
Coval M L |
Method of producing intravenously injectable gamma globulin
|
GB1603244A
(en)
*
|
1977-05-20 |
1981-11-18 |
Max Planck Gesellschaft |
Medicaments for the suppression of pathological processes
|
JPS5822085B2
(ja)
*
|
1977-07-19 |
1983-05-06 |
株式会社ミドリ十字 |
静注用ガンマ・グロブリン製剤
|
US4296027A
(en)
*
|
1977-08-31 |
1981-10-20 |
The Regents Of The University Of Minnesota |
Pure intravenous human and animal gamma globulins
|
AT359641B
(de)
|
1978-09-19 |
1980-11-25 |
Immuno Ag |
Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
|
US4272521A
(en)
|
1979-07-16 |
1981-06-09 |
Cutter Laboratories, Inc. |
Purified immune serum globulin
|
US4374763A
(en)
*
|
1979-09-17 |
1983-02-22 |
Morishita Pharmaceutical Co., Ltd. |
Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
|
JPS591691B2
(ja)
*
|
1981-05-29 |
1984-01-13 |
株式会社ミドリ十字 |
静注用γ−グロブリン製剤
|
JPS57206608A
(en)
|
1981-05-29 |
1982-12-18 |
Mochida Pharmaceut Co Ltd |
Production of gamma-globulin for intravenous injection
|
JPS57203017A
(en)
*
|
1981-06-09 |
1982-12-13 |
Fujirebio Inc |
Purifying method of immunoglobulin
|
JPS5821623A
(ja)
*
|
1981-07-28 |
1983-02-08 |
Tetsuzo Sugizaki |
抗原抗体複合体沈着疾患治療剤
|
US4499073A
(en)
*
|
1981-08-24 |
1985-02-12 |
Cutter Laboratories, Inc. |
Intravenously injectable immune serum globulin
|
US4396608A
(en)
*
|
1981-08-24 |
1983-08-02 |
Cutter Laboratories |
Intravenously injectable immune serum globulin
|
JPS58180433A
(ja)
*
|
1982-04-16 |
1983-10-21 |
Fujirebio Inc |
免疫グロブリンから抗補体作用物質の除去法
|
US4465670A
(en)
*
|
1982-07-23 |
1984-08-14 |
Dainippon Pharmaceutical Co., Ltd. |
Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor
|
US4439421A
(en)
*
|
1982-08-30 |
1984-03-27 |
Baxter Travenol Laboratories, Inc. |
Stabilized gamma globulin concentrate
|
EP0116571B2
(fr)
*
|
1982-08-30 |
1997-10-29 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Procede de fabrication de compositions contenant de la gamma globuline
|
JPS5967228A
(ja)
*
|
1982-10-07 |
1984-04-16 |
Green Cross Corp:The |
寒冷不溶性グロブリンの凍結乾燥方法
|
US4639513A
(en)
*
|
1984-02-02 |
1987-01-27 |
Cuno Inc. |
Intravenously injectable immunoglobulin G (IGG) and method for producing same
|
JPS6112629A
(ja)
*
|
1984-06-28 |
1986-01-21 |
Lion Corp |
口腔内組成物
|
US4732863A
(en)
*
|
1984-12-31 |
1988-03-22 |
University Of New Mexico |
PEG-modified antibody with reduced affinity for cell surface Fc receptors
|
US4597966A
(en)
*
|
1985-01-09 |
1986-07-01 |
Ortho Diagnostic Systems, Inc. |
Histidine stabilized immunoglobulin and method of preparation
|
FR2582515B1
(fr)
*
|
1985-05-30 |
1988-11-04 |
Merieux Inst |
Procede de preparation de gamma-gobulines administrables par voie intraveineuse et gamma-globulines obtenues
|
JPH0662436B2
(ja)
*
|
1986-05-19 |
1994-08-17 |
株式会社ミドリ十字 |
静注用免疫グロブリン製剤の製造方法
|
DE3641115A1
(de)
|
1986-12-02 |
1988-06-16 |
Lentia Gmbh |
Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
|
AT389817B
(de)
*
|
1987-01-22 |
1990-02-12 |
Schwab & Co Ges Mbh |
Verfahren zur herstellung eines in fluessiger form stabilen immunglobulins zur intravenoesen anwendung
|
US5219578A
(en)
*
|
1991-02-25 |
1993-06-15 |
Innovet, Inc. |
Composition and method for immunostimulation in mammals
|
US5525519A
(en)
*
|
1992-01-07 |
1996-06-11 |
Middlesex Sciences, Inc. |
Method for isolating biomolecules from a biological sample with linear polymers
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
IT1284076B1
(it)
*
|
1996-06-27 |
1998-05-08 |
Dox Al Italia Spa |
Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro
|
CA2232420A1
(fr)
*
|
1997-03-19 |
1998-09-19 |
The Green Cross Corporation |
Preparation d'immunoglobuline et processus de production
|
AU6914998A
(en)
|
1997-04-07 |
1998-10-30 |
Cangene Corporation |
Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
|
US7541020B2
(en)
*
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US6991790B1
(en)
*
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
AU4314900A
(en)
*
|
1999-04-28 |
2000-11-17 |
Yamanouchi Pharmaceutical Co., Ltd. |
Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
|
US20020098182A1
(en)
*
|
2000-09-28 |
2002-07-25 |
Richard Weisbart |
Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
ES2332402T5
(es)
*
|
2000-10-12 |
2018-05-14 |
Genentech, Inc. |
Formulaciones de proteína concentradas de viscosidad reducida
|
US20040180045A1
(en)
*
|
2001-09-28 |
2004-09-16 |
Richard Weisbart |
Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
SI2335725T1
(sl)
*
|
2003-04-04 |
2017-01-31 |
Genentech, Inc. |
Visokokoncentrirane formulacije protiteles in proteinov
|
BRPI0514435B8
(pt)
|
2004-08-20 |
2021-05-25 |
American Nat Red Cross |
isolamento sequêncial de proteínas e esquemas de purificação através de cromatografia por afinidade
|
WO2007008697A2
(fr)
*
|
2005-07-08 |
2007-01-18 |
University Of Chicago |
Compositions et methodes pour le repliement de proteines denaturees
|
US20070049732A1
(en)
*
|
2005-09-01 |
2007-03-01 |
Zurlo Eugene J |
Ultra-high yield intravenous immune globulin preparation
|
US8293242B2
(en)
*
|
2005-09-01 |
2012-10-23 |
Plasma Technologies, Llc |
Ultra-high yield of alpha-1-anti-trypsin
|
US7879332B2
(en)
*
|
2005-09-01 |
2011-02-01 |
Plasma Technologies, Llc |
Ultra-high yield intravenous immune globulin preparation
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
SG174258A1
(en)
*
|
2009-03-06 |
2011-10-28 |
Genentech Inc |
Antibody formulation
|
MX2012003282A
(es)
|
2009-09-17 |
2012-04-30 |
Baxter Healthcare Sa |
Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
|
MX2012010198A
(es)
|
2010-03-01 |
2012-10-03 |
Bayer Healthcare Llc |
Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
|
ES2381828B1
(es)
|
2012-03-20 |
2012-11-16 |
Grifols, S.A. |
PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|